Loading

Juncell Therapeutics

June 04, 2024
Company Presentation
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 4
Juncell Therapeutics is focused on innovative TIL (tumor-infiltrating lymphocyte) therapies for solid tumors, including both natural TIL programs and non-viral gene-modified TIL programs. Our TIL therapies are featured with an improved safety profile without compromising efficacy, thanks to the enhanced TIL manufactured by DeepTIL® cell expansion platform. DeepTIL® enables TIL to be potent enough so that the high-dose IL-2 combination could be eliminated and the intensity of pretreatment could be much lower. Juncell also established the NovaGMP® non-viral vector gene-modification platform, which is of high efficiency (> 45% in the final cell product) and low cost of goods (< 10% of lentiviral vector). Juncell natural TIL therapy GC101 and gene-engineered TIL therapy GC203 have shown promising efficacy in melanoma, lung cancer, ovarian cancer, pancreatic cancer, cervical cancer, endometrial cancer, bile duct cancer, glioma and breast cancer, including 6 complete responses.
Juncell Therapeutics
Company Website: https://www.juncell.com/en
Lead Product in Development: GC101 natural TIL therapy
Number Of Unlicensed Products (For Which You Are Seeking Partners): 2

Company HQ City

Shanghai

Company HQ State

Shanghai

Company HQ Country

China

CEO/Top Company Official

Huajun Jin, PhD, CEO

Development Phase of Primary Product

Phase I
Speakers
Ross Ma, PhD
Head of Business Development
Juncell Therapeutics
Back to Session List

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS